ClinicalTrials.gg
Not yet recruitingNCT079412064sightUpdated Nov 17, 2026

A Phase 1b Study of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Non-Gain-of-Function Variants

A Phase 1 interventional study of Radiprodil and Placebo in GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function, sponsored by GRIN Therapeutics, Inc.. Not yet recruiting. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by GRIN Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
1 Month to 18 Years
Sex
All
01

Study summary

This is a multinational, multicenter, randomized, double-blinded, placebo-controlled, Phase 1b study with an open-label extension (OLE) to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related neurodevelopmental disorder (GRIN-NDD) in children with a genetic variant characterized as non-gain-of-function.

This study will consist of Part A (blinded, placebo-controlled) and Part B (blinded transition followed by an OLE).

Participants will be randomized in a 2:1 ratio to receive active drug (radiprodil) or matching placebo (Part A) and stratified by functional characterization (either indeterminant, LoF, or no effect). Following completion of Part A, all eligible participants (including those previously on placebo) may continue into the open-label extension period (Part B) to receive radiprodil.

The placebo-controlled portion is expected to be approximately 17 weeks for participants in Part A and at least 12 months for participants in Part B.

Read the detailed description

Participants are assigned in a 2:1 ratio to receive either radiprodil or placebo during Part A with the opportunity to receive radiprodil in the Part B OLE.

This study is divided into the following parts:

Part A: Randomized, double-blind, placebo-controlled

  • Screening/Observation Period: To assess eligibility (approximately 5 weeks)
  • Titration Period (approximately 4 weeks): Titration of radiprodil or placebo to target dose
  • Maintenance Period (Part A): Target dose of radiprodil or placebo maintained for 8 weeks
  • Tapering and Follow-up Period: Gradual decrease and Follow-up Period for participants not entering Part B

Part B: Open-label safety follow-up period

  • Blinded Titration Period (approximately 4 weeks): Titration of radiprodil to target dose
  • Open-Label Treatment Period: Participants will continue to receive radiprodil until such time as either the participant withdraws/is withdrawn from the study, Sponsor terminates the study, or market access is available
  • Tapering and Follow-up Period: Gradual decrease and follow-up observation period for participants upon leaving the study
02

Conditions studied

  • GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function

Keywords

  • GRIN-NDD
03

In context

Lead sponsor

GRIN Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A, Participant:

  • Diagnosed with GRIN-NDD with GRIN1, GRIN2A, GRIN2B, or GRIN2D gene variants known to result in a functional characterization that is loss of function, indeterminant, or no effect
  • Inadequately controlled seizures of any type with EEG abnormalities per EEG collected within 12 months of Screening or during the Screening Period
  • Receiving at least 1 standard antiseizure medication (ASM)
  • On a stable dose of standard ASM for at least 4 weeks prior to screening and should remain on stable dose throughout study participation
  • Nonpharmacological treatments such as ketogenic diet should remain stable throughout study participation
  • Participant's caregivers are willing and able to complete entries in the eDiary on a daily basis and have demonstrated compliance

Part B, Participant:

- Has completed Part A and is eligible to continue study participation according to the judgment of the Investigator and Sponsor.

Exclusion criteria

Exclusion Criteria:

PART A, Participant:

  • Has medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation or study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.
  • Is receiving >4 standard ASMs at screening
  • Has a body weight of less than 5 kg at screening
  • Participant or caregiver is unwilling or unable to comply with all study procedures for the duration of the study.
  • Has clinically significant laboratory or abnormalities according to the judgment of the Investigator or Sponsor
  • Has severe hepatic dysfunction ( grade C)
  • Has a history of brain surgery within 6 months of randomization for epilepsy or any other reason
  • Is receiving treatment with prohibited concomitant drugs such as agonists or antagonists of the glutamate receptor, including but not limited to felbamate, memantine, and perampanel
  • Is receiving treatment with a strong inhibitor (eg, itraconazole or some antimicrobials that are strong inhibitors) that has not been discontinued at least 5 half-lives prior to the planned first dose of radiprodil
  • Has received any prior gene therapy
  • Is on treatment with hormonal therapy such as adrenocorticotrophic hormone or prednisolone

Part B Participant:

  • Has clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation of study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.
  • Participant or caregiver is unwilling or unable to comply with all study procedures for the duration of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Radiprodil oral suspension

    Liquid suspension of radiprodil, at varying concentrations depending on participant's weight. The following dose-escalation regimen (twice daily \[BID\]) will be used: Titration Period Visit 1 (Visit T1): Dose 1, Visit T2: Dose 2, Visit T3: Dose 3, Visit T4: Maintenance Dose.

    Drug: Radiprodil

  • Placebo comparator
    Placebo-to-match radiprodil oral suspension

    Liquid suspension of placebo matching radiprodil oral suspension and dose-escalation regimen.

    Drug: Placebo

Interventions

  • DrugRadiprodil

    Radiprodil oral suspension

  • DrugPlacebo

    Placebo-to-match radiprodil oral suspension

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs)

    Number and percentage of participants experiencing adverse events (AEs). AEs will be assessed by frequency, type, severity, and duration. Treatment-emergent AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by System Organ Class and Preferred Term.

    Time frame: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).

  2. Serious Adverse Events (SAEs)

    Number and percentage of participants experiencing serious adverse events (SAEs). SAEs will be assessed by frequency, type, severity, and duration, including treatment-emergent SAEs and SAEs considered related to investigational product.

    Time frame: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).

  3. Adverse Drug Reactions (ADRs)

    Number and percentage of participants experiencing adverse drug reactions (ADRs). ADRs will be assessed by frequency, type, severity, and duration and summarized by functional characterization, study part, and overall.

    Time frame: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).

  4. Change From Baseline in Blood Pressure

    Change from Baseline in blood pressure (mmHg), assessed at scheduled study visits. Observed values and changes from Baseline will be summarized using descriptive statistics.

    Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

  5. Change From Baseline in Pulse Rate

    Change from Baseline in pulse rate (beats per minute), assessed at scheduled study visits. Observed values and changes from Baseline will be summarized using descriptive statistics.

    Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

  6. Physical Examination Findings

    Number and percentage of participants with abnormal physical or neurological examination findings. Findings will be listed, and findings indicative of adverse events will be included in adverse event summaries.

    Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

  7. Change From Baseline in ECG Pulse Rate

    Change from Baseline in pulse rate measured by 12-lead electrocardiogram (ECG), expressed in beats per minute (bpm).

    Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

  8. Change From Baseline in ECG RR Interval

    Change from Baseline in the RR interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

    Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

  9. Change From Baseline in ECG PR Interval

    Change from Baseline in the PR interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

    Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

  10. Change From Baseline in ECG QRS Duration

    Change from Baseline in QRS duration measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

    Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

  11. Change From Baseline in ECG QT Interval

    Change from Baseline in the QT interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

    Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

  12. Change From Baseline in ECG QTcF Interval

    Change from Baseline in the QT interval corrected using Fridericia's formula (QTcF), measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

    Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

  13. Clinically Significant Changes in Clinical Laboratory Parameters

    Number and percentage of participants with clinically significant abnormalities or changes in clinical laboratory parameters, including hematology, serum chemistry, and coagulation assessments. Laboratory values and changes from Baseline will be summarized, and clinically significant abnormal values listed separately.

    Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

  14. Emergence of New Seizure Types

    Number and percentage of participants experiencing new seizure types compared with Baseline. Emergence of new seizure types will be tabulated overall and by seizure type at scheduled assessments.

    Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

  15. Occurrence of Suicidal Ideation

    Number and percentage of participants experiencing suicidal ideation at any post-Baseline assessment, based on the Columbia-Suicide Severity Rating Scale (C-SSRS) or investigator assessment, as appropriate for the participant.

    Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

  16. Occurrence of Suicidal Behavior

    Number and percentage of participants experiencing suicidal behavior at any post-Baseline assessment, based on the Columbia-Suicide Severity Rating Scale (C-SSRS) or investigator assessment, as appropriate for the participant.

    Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Secondary outcomes

  1. Plasma Concentration of Radiprodil

    Plasma concentrations of radiprodil will be measured at predefined pharmacokinetic (PK) sampling timepoints.

    Time frame: From first dose through study completion, including Part A (12 weeks of treatment) and Part B (anticipated at least 12 months).

  2. Change From Baseline in SERIAS Green Light Days

    Change from Baseline to the end of the Part A Maintenance Period in the number of green light days, assessed using the Seizure-Related Impact Assessment Scale (SERIAS) and captured in the daily electronic diary (eDiary).

    Time frame: Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).

  3. Change From Baseline in SERIAS Yellow Light Days

    Change from Baseline to the end of the Part A Maintenance Period in the number of yellow light days, assessed using SERIAS and captured in the daily eDiary.

    Time frame: Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).

  4. Change From Baseline in SERIAS Red Light Days

    Change from Baseline to the end of the Part A Maintenance Period in the number of red light days, assessed using SERIAS and captured in the daily eDiary.

    Time frame: Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).

  5. Change From Baseline in Total Countable Seizure Frequency per 28 Days

    Change from Baseline in total countable seizure frequency normalized to 28 days during the Part A Maintenance Period (Weeks 1 through 8), as recorded in the daily seizure eDiary.

    Time frame: Baseline (last 4 weeks before randomization) through Part A Maintenance Period (8 weeks).

  6. Change From Baseline in EEG Spike Rate

    Change from Baseline in electroencephalogram (EEG) spike rate, expressed as spikes per hour, during the Part A Maintenance Period.

    Time frame: Baseline through Part A Maintenance Period (Weeks 1 through 8).

  7. Change From Baseline in EEG Background Activity

    Change from Baseline in electroencephalogram (EEG) background activity during the Part A Maintenance Period.

    Time frame: Baseline through Part A Maintenance Period (Weeks 1 through 8).

  8. Percentage of Participants With at Least 50% Reduction in Total Countable Seizure Frequency

    Percentage of participants achieving at least a 50% reduction in total countable seizure frequency per 28 days from Baseline (the last 4 weeks before randomization) to the entire Part A Maintenance Period.

    Time frame: Baseline (last 4 weeks before randomization) to the end of Part A Maintenance Period (8 weeks).

  9. Percentage of Participants With at Least 50% Reduction in Total Seizure Frequency

    Percentage of participants achieving at least a 50% reduction in total seizure frequency compared with Baseline.

    Time frame: Baseline through Part A and Part B, as assessed.

  10. Percent Change From Baseline in Total Countable Seizure Frequency

    Percent change from Baseline in total countable seizure frequency normalized to 28 days. Percent change is calculated relative to the Baseline seizure frequency.

    Time frame: Baseline through Part A and Part B, as assessed.

  11. Proportion of Seizure-Free Days

    Proportion of days without seizures during the assessment period, based on seizure data recorded in the daily eDiary.

    Time frame: Baseline through Part A and Part B, as assessed.

  12. Longest Interval of Seizure Freedom

    Longest consecutive interval without seizures during the assessment period, based on seizure data recorded in the daily eDiary.

    Time frame: Baseline through Part A and Part B, as assessed.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Oct 2027, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 17, 2026
StartEst.
Dec 2026
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941206
Lead sponsor
GRIN Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Clinical Operations
Contact
ClinicalTrials@GrinTherapeutics.com
+1-877-225-0014
Michelle Pritikin
study director · GRIN Therapeutics, Inc.
Aneeta Saxena
study director · GRIN Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion